🔗 Share this article Users Discontinuing Weight-Loss Medications Regain Pounds Far More Rapidly Than Those on Conventional Diets Obesity treatment often requires ongoing approaches. New research suggests that people who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who halt conventional lifestyle regimens. Published data in a prominent health publication demonstrates that while obese individuals often shed about a fifth of their body weight while undergoing treatment, the weight returns at an average rate of 0.8 kg per month upon discontinuation. "Users using such drugs must be cognizant of the danger of rapid weight regain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb. That rate of recovery means a reversion to starting weight in about one and a half years. Weighing Therapies The study, which looked at dozens of studies involving over 9,000 of patients, contrasted the effects of the injectable medications with other pills. The team emphasize that people who lose weight through dieting generally see a more gradual weight regain—approximately 100 grams monthly—once they finish. Explaining the Fast Regain Experts propose the way of the injections is key to understanding the accelerated rebound. These medications imitate a natural hormone called GLP-1, which helps regulate hunger. "Long-term administration of GLP-1 concentrations several times higher than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher. "Withdrawal of this medication results in appetite is uncontrolled, making excessive eating much more probable." A Chronic Disease? Medical guidelines recommend the injections for individuals with obesity-related health risks, accompanied by prescribed diet and exercise modifications. Professionals say that, due to the high risk of relapse, the treatment should be considered ongoing. This perspective is echoed by drug manufacturers, who say that the findings "highlight the chronic character of obesity," comparing it to managing conditions like hypertension. User Accounts Individuals who have come off the jabs explain a powerful return of hunger. "I experienced a switch that goes on and you're instantly ravenous," described one woman. This difficulty is worsened if patients have not developed sustainable lifestyle or habit modifications during therapy. Widespread Interest Survey data suggest that millions of adults in the UK have used these injections in the last 12 months, with desire remaining high. Adoption is higher among women than men. The 40s and 50s demographic shows the greatest usage rates. Many obtain the drugs through private healthcare rather than the NHS. Ultimately, researchers stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic solution and long-term success hinges on integrated behavioural changes.
Obesity treatment often requires ongoing approaches. New research suggests that people who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who halt conventional lifestyle regimens. Published data in a prominent health publication demonstrates that while obese individuals often shed about a fifth of their body weight while undergoing treatment, the weight returns at an average rate of 0.8 kg per month upon discontinuation. "Users using such drugs must be cognizant of the danger of rapid weight regain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb. That rate of recovery means a reversion to starting weight in about one and a half years. Weighing Therapies The study, which looked at dozens of studies involving over 9,000 of patients, contrasted the effects of the injectable medications with other pills. The team emphasize that people who lose weight through dieting generally see a more gradual weight regain—approximately 100 grams monthly—once they finish. Explaining the Fast Regain Experts propose the way of the injections is key to understanding the accelerated rebound. These medications imitate a natural hormone called GLP-1, which helps regulate hunger. "Long-term administration of GLP-1 concentrations several times higher than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher. "Withdrawal of this medication results in appetite is uncontrolled, making excessive eating much more probable." A Chronic Disease? Medical guidelines recommend the injections for individuals with obesity-related health risks, accompanied by prescribed diet and exercise modifications. Professionals say that, due to the high risk of relapse, the treatment should be considered ongoing. This perspective is echoed by drug manufacturers, who say that the findings "highlight the chronic character of obesity," comparing it to managing conditions like hypertension. User Accounts Individuals who have come off the jabs explain a powerful return of hunger. "I experienced a switch that goes on and you're instantly ravenous," described one woman. This difficulty is worsened if patients have not developed sustainable lifestyle or habit modifications during therapy. Widespread Interest Survey data suggest that millions of adults in the UK have used these injections in the last 12 months, with desire remaining high. Adoption is higher among women than men. The 40s and 50s demographic shows the greatest usage rates. Many obtain the drugs through private healthcare rather than the NHS. Ultimately, researchers stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic solution and long-term success hinges on integrated behavioural changes.